联环药业
(600513)
| 流通市值：41.85亿 | | | 总市值：41.85亿 |
| 流通股本：2.85亿 | | | 总股本：2.85亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,570,814,170.07 | 810,625,785.82 | 2,711,858,051.35 | 2,082,459,109.35 |
| 营业收入 | 1,570,814,170.07 | 810,625,785.82 | 2,711,858,051.35 | 2,082,459,109.35 |
| 二、营业总成本 | 1,548,886,885.84 | 800,833,222.39 | 2,711,961,483.08 | 2,028,444,912.55 |
| 营业成本 | 1,120,395,602.36 | 595,627,162.11 | 1,768,226,292.33 | 1,364,226,995.64 |
| 税金及附加 | 10,867,365.85 | 5,292,852.48 | 21,157,729.5 | 14,655,363.82 |
| 销售费用 | 223,598,410.04 | 104,528,261.15 | 501,460,647.32 | 374,198,002.09 |
| 管理费用 | 112,257,479.16 | 58,012,271.6 | 183,718,858.1 | 143,279,509.29 |
| 研发费用 | 62,952,648.68 | 28,659,901.36 | 205,274,406.68 | 107,582,797.46 |
| 财务费用 | 18,815,379.75 | 8,712,773.68 | 32,123,549.15 | 24,502,244.25 |
| 其中:利息费用 | 18,254,517.11 | 8,370,386.24 | 32,290,196.04 | 24,491,376.61 |
| 其中:利息收入 | 411,133.86 | -17,715.07 | 654,232.91 | 429,638.24 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -3,135,351.67 | -225,812.48 | -10,155,426.27 | -2,977,730.95 |
| 资产处置收益 | 32,137.12 | 908.6 | -77,537.02 | - |
| 资产减值损失(新) | -300,699.19 | 215,067.77 | -10,860,329.06 | -923,558.06 |
| 信用减值损失(新) | -1,047,295.76 | -1,501,507.95 | -6,583,059.54 | 1,503,160.7 |
| 其他收益 | 7,645,389.06 | 2,701,864 | 17,380,879.02 | 7,842,433.2 |
| 四、营业利润 | 25,121,463.79 | 10,983,083.37 | -10,398,904.6 | 59,458,501.69 |
| 加:营业外收入 | 230,001.57 | 118,039.65 | 433,907.38 | 538,622.86 |
| 减:营业外支出 | 2,947,051.93 | 500,626.52 | 77,640,671 | 61,494,345.92 |
| 五、利润总额 | 22,404,413.43 | 10,600,496.5 | -87,605,668.22 | -1,497,221.37 |
| 减:所得税费用 | 7,648,108.72 | 3,238,111.33 | -3,452,873.66 | 26,225,175.05 |
| 六、净利润 | 14,756,304.71 | 7,362,385.18 | -84,152,794.56 | -27,722,396.42 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 14,756,304.71 | 7,362,385.18 | -84,152,794.56 | -27,722,396.42 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 10,521,803.08 | 6,424,752.09 | -98,332,448.41 | -35,062,142.12 |
| 少数股东损益 | 4,234,501.63 | 937,633.09 | 14,179,653.85 | 7,339,745.7 |
| 扣除非经常损益后的净利润 | 8,751,772.59 | 5,611,567.53 | -32,754,164.06 | 22,297,641.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.02 | -0.34 | -0.12 |
| (二)稀释每股收益 | 0.04 | 0.02 | -0.34 | -0.12 |
| 八、其他综合收益 | 98,348.85 | 634,095.24 | -124,595.73 | -104,216.08 |
| 归属于母公司股东的其他综合收益 | 98,348.85 | 634,095.24 | -124,595.73 | -104,216.08 |
| 九、综合收益总额 | 14,854,653.56 | 7,996,480.42 | -84,277,390.29 | -27,826,612.5 |
| 归属于母公司股东的综合收益总额 | 10,620,151.93 | 7,058,847.33 | -98,457,044.14 | -35,166,358.2 |
| 归属于少数股东的综合收益总额 | 4,234,501.63 | 937,633.09 | 14,179,653.85 | 7,339,745.7 |
| 公告日期 | 2026-08-29 | 2026-04-28 | 2026-04-21 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |